JP2022542884A - Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 - Google Patents

Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 Download PDF

Info

Publication number
JP2022542884A
JP2022542884A JP2022504569A JP2022504569A JP2022542884A JP 2022542884 A JP2022542884 A JP 2022542884A JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022542884 A JP2022542884 A JP 2022542884A
Authority
JP
Japan
Prior art keywords
amino acid
fcrn
acid position
binding
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022504569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542884A5 (https=
JPWO2021016571A5 (https=
Inventor
ブリアン・マックネス
ファウェイ・チウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2022542884A publication Critical patent/JP2022542884A/ja
Publication of JP2022542884A5 publication Critical patent/JP2022542884A5/ja
Publication of JPWO2021016571A5 publication Critical patent/JPWO2021016571A5/ja
Priority to JP2025051382A priority Critical patent/JP2025098167A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022504569A 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 Pending JP2022542884A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025051382A JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878541P 2019-07-25 2019-07-25
US62/878,541 2019-07-25
PCT/US2020/043533 WO2021016571A2 (en) 2019-07-25 2020-07-24 Methods of treating antibody-mediated disorders with fcrn antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025051382A Division JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Publications (3)

Publication Number Publication Date
JP2022542884A true JP2022542884A (ja) 2022-10-07
JP2022542884A5 JP2022542884A5 (https=) 2023-07-31
JPWO2021016571A5 JPWO2021016571A5 (https=) 2023-07-31

Family

ID=72087159

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504569A Pending JP2022542884A (ja) 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Country Status (13)

Country Link
US (1) US20210024620A1 (https=)
EP (1) EP4004039A2 (https=)
JP (2) JP2022542884A (https=)
KR (1) KR20220038432A (https=)
CN (1) CN114466663B (https=)
AU (1) AU2020315925A1 (https=)
BR (1) BR112022001255A2 (https=)
CA (1) CA3148764A1 (https=)
CO (1) CO2022001164A2 (https=)
IL (1) IL290101A (https=)
MX (1) MX2022001038A (https=)
TW (1) TW202120539A (https=)
WO (1) WO2021016571A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71603A (fr) 2022-07-27 2025-05-30 Ablynx Nv Polypeptides se liant à un épitope spécifique du récepteur fc néonatal
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン．ヴェー． 新生児型ｆｃ受容体に結合するポリペプチド
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
AU2024329349A1 (en) 2023-08-23 2026-04-09 Sanofi Ctla-4-based lysosomal degraders and uses thereof
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
AR134267A1 (es) 2023-11-08 2025-12-17 Sanofi Sa Degradador lisosómico basado en cd25 y usos del mismo
WO2025144848A1 (en) * 2023-12-27 2025-07-03 Vetmab Biosciences, Inc. FcRn ANTAGONISTS FOR VETERINARY USE

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519860A (ja) * 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP2014528906A (ja) * 2011-09-30 2014-10-30 中外製薬株式会社 抗原クリアランスを促進するＦｃＲｎ結合ドメインを有する治療用抗原結合分子
JP2018509413A (ja) * 2015-03-09 2018-04-05 アルゲン−エックス ビーブイビーエー ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
JP2021511830A (ja) * 2018-01-26 2021-05-13 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2012132067A1 (ja) * 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
KR20210094669A (ko) * 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
US20170211876A1 (en) * 2014-06-12 2017-07-27 Hoffmann-La Roche Inc. Method for selecting antibodies with modified fcrn interaction
RS59340B1 (sr) * 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
EP3625251A1 (en) * 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519860A (ja) * 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP2014528906A (ja) * 2011-09-30 2014-10-30 中外製薬株式会社 抗原クリアランスを促進するＦｃＲｎ結合ドメインを有する治療用抗原結合分子
JP2018509413A (ja) * 2015-03-09 2018-04-05 アルゲン−エックス ビーブイビーエー ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
JP2021511830A (ja) * 2018-01-26 2021-05-13 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
JP7399880B2 (ja) * 2018-01-26 2023-12-18 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J OF NUCLEAR MEDICINE, vol. 55, no. 7, JPN6024023906, 2014, pages 1204 - 1207, ISSN: 0005643535 *
MABS, vol. 11, no. 7, JPN6024023905, 18 July 2019 (2019-07-18), pages 1276 - 1288, ISSN: 0005643536 *

Also Published As

Publication number Publication date
CA3148764A1 (en) 2021-01-28
AU2020315925A1 (en) 2022-03-03
KR20220038432A (ko) 2022-03-28
CN114466663B (zh) 2026-01-02
WO2021016571A3 (en) 2021-03-04
US20210024620A1 (en) 2021-01-28
CO2022001164A2 (es) 2022-03-08
CN114466663A (zh) 2022-05-10
BR112022001255A2 (pt) 2022-06-14
JP2025098167A (ja) 2025-07-01
MX2022001038A (es) 2022-04-26
TW202120539A (zh) 2021-06-01
WO2021016571A2 (en) 2021-01-28
IL290101A (en) 2022-03-01
EP4004039A2 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7399880B2 (ja) ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
JP2025098167A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
JP7631276B2 (ja) Ｖｅｇｆ－ａ及びａｎｇ２に結合する抗体及び使用方法
TW202003570A (zh) 抗trem-1抗體及其用途
AU2018382593A1 (en) Variants with Fc fragment having an increased affinity for FcRn and an increased affinity for at least one receptor of the Fc fragment
JP6522585B2 (ja) Ｃｘｃｒ５に対するモノクローナル抗体
WO2022061236A1 (en) High affinity anti-ige antibodies
CN115175736A (zh) 杂交抗体
TW202306584A (zh) 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
RU2795592C2 (ru) Варианты fc с повышенным связыванием с fcrn и пролонгированным периодом полувыведения
BR122024014725A2 (pt) Usos de um antagonista de fcrn no tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn, polipeptídeos isolados, e composições farmacêuticas compreendendo os mesmos
TW202607021A (zh) 結合ｔｓｌｐ之抗體及使用方法
HK40086991A (zh) 与vegf-a和ang2结合的抗体及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326